Reports Q3 revenue $180.9M, consensus $179.52M. “The overall business performed well in the quarter, as demonstrated by accelerating volume growth in our genomics business and accelerating revenue growth in our data and services business, specifically within Insights,” said Eric Lefkofsky, Founder and CEO of Tempus. “We’re also excited to announce the pending acquisition of Ambry Genetics, which broadens our testing portfolio, expands our disease coverage, and enhances the types of products we can offer to our biotech and pharmaceutical partners. In addition, Ambry is uniquely positioned given that its revenues are currently growing at north of 25% a year and it generates meaningful EBITDA and cash flow.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood’s ARK Investment bought 170.6K shares of Tempus AI today
- Largest borrow rate increases among liquid names
- Avacta,Tempus AI enter collaboration for AI-driven drug development
- Cathie Wood’s ARK Investment bought 103K shares of Tempus AI today
- Tempus AI price target raised to $57 from $48 at Loop Capital